Analysts Set CG Oncology, Inc. (NASDAQ:CGON) Price Target at $83.18

Shares of CG Oncology, Inc. (NASDAQ:CGON) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $83.1818.

A number of research firms recently commented on CGON. Truist Financial increased their price target on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Piper Sandler lifted their price objective on shares of CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Wall Street Zen downgraded shares of CG Oncology from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th.

CG Oncology Stock Performance

Shares of CGON opened at $78.23 on Friday. The stock has a 50 day moving average price of $71.69 and a two-hundred day moving average price of $65.80. The firm has a market capitalization of $6.93 billion, a P/E ratio of -29.08 and a beta of 0.23. CG Oncology has a 52 week low of $25.25 and a 52 week high of $80.97.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.24). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $0.36 million. CG Oncology had a negative return on equity of 25.20% and a negative net margin of 3,602.68%. On average, equities analysts forecast that CG Oncology will post -3.27 earnings per share for the current year.

Insider Buying and Selling

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the completion of the sale, the director owned 5,000 shares in the company, valued at approximately $350,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Brian Guan-Chyun Liu bought 371,085 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were purchased at an average cost of $66.87 per share, for a total transaction of $24,814,453.95. Following the transaction, the director owned 1,886,236 shares in the company, valued at approximately $126,132,601.32. This represents a 24.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have sold 38,129 shares of company stock worth $2,738,357. 4.80% of the stock is owned by insiders.

Institutional Trading of CG Oncology

A number of institutional investors and hedge funds have recently modified their holdings of CGON. AQR Capital Management LLC bought a new stake in CG Oncology during the first quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in CG Oncology by 18.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock worth $876,000 after purchasing an additional 5,442 shares during the last quarter. Millennium Management LLC grew its stake in CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after purchasing an additional 347,055 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after purchasing an additional 53,461 shares during the period. Finally, Legal & General Group Plc increased its position in shares of CG Oncology by 12.3% during the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock valued at $1,153,000 after purchasing an additional 4,847 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.